Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease

New York, NY — October 22, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor.  These findings may explain…

Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

New York, NY — September 3, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the…

Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

New York, NY — September 3, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the…

Anavex Raises $2.6-Million in Private Placement and Conversion of Liabilities, Enters Into $10-Million Financing Commitment and Appoints CEO

New York, NY — July 8, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced the closing of $2.6-million in a private placement financing and conversion of liabilities and an agreement with institutional investor Lincoln Park Capital Fund, LLC (“Lincoln Park Capital”) for a funding commitment of up to $10-million…

ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer’s Disease

New data presented at International Conference on Alzheimer’s and Parkinson’s Diseases Vancouver, BC — March 12, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today announced more promising new data for ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. In a scientific study conducted in France at the University of Montpellier and…